Skip to main content

Table 2 Contingency analysis of cytoplasmic phosphorylated RKIP (c-pRKIP), nuclear phosphorylated RKIP (n-pRKIP) and nuclear STAT3 (n-STAT3) expression and tumor Grade and LVI status

From: RKIP phosphorylation and STAT3 activation is inhibited by oxaliplatin and camptothecin and are associated with poor prognosis in stage II colon cancer patients

Marker Grade p-value LVI p-value
  Low High   Absent Present  
c-pRKIP n (%) n (%) 0.024 n (%) n (%) 0.29
0, 1+, 2+ 46 (74%) 16 (26%)   55 (89%) 7 (11%)  
3+ 59 (89%) 7 (11%)   62 (94%) 4 (6%)  
n-pRKIP n (%) n (%) 0.399 n (%) n (%) 0.06
0 16 (89%) 2 (11%)   18 (100%) 0 (0%)  
1+, 2+, 3+ 90 (81%) 21 (19%)   100 (90%) 11 (10%)  
n-STAT3 n (%) n (%) 0.064 n (%) n (%) 0.038
0 19 (95%) 1 (5%)   20 (100%) 0 (0%)  
1+, 2+, 3+ 86 (80%) 22 (20%)   96 (89%) 12 (11%)  
  1. The numbers and the percentages of cases are provided.